Xu Huanli, Inagaki Yoshinori, Tang Wei, Guo Qian, Wang Fengshan, Seyama Yasuji, Midorikawa Yutaka, Gai Ruoyan, Kokudo Noribim, Sugawara Yasuhiko, Nakata Munehiro, Makuuchi Masatoshi
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Hepatogastroenterology. 2008 Nov-Dec;55(88):2000-4.
BACKGROUND/AIMS: KL-6 mucin is a type of MUC1 mucin. Previous immunohistochemical studies by the authors revealed that, in liver cancer tissues, KL-6 mucin expressed only in intrahepatic cholangiocarcinoma (CC) but not in hepatocellular carcinoma (HCC). The current study performed serological analysis to evaluate KL-6 mucin levels in sera from various liver cancer patients and healthy individuals.
Enzyme-linked immunosorbent assay was used to measure KL-6 mucin levels in sera from 8 CC patients, 27 HCC patients, 30 metastatic liver cancer (MC) patients, and 19 healthy individuals.
Serum KL-6 mucin levels were significantly higher in CC patients than in healthy individuals (p<0.0001), HCC patients (p<0.0001), and MC patients (p<0.001). Receiver operating characteristic analysis determined the cut-off level of serum KL-6 mucin levels to be 240 U/mL (CC vs. healthy, p<0.001) or 248 U/mL (CC vs. HCC, p<0.001). Using 248 U/mL as a cut-off value, the positive rate for CC patients, healthy individuals, and HCC patients was 100.0%, 15.8%, and 18.5%, respectively.
Elevation of serum KL-6 levels was detectable in CC patients. Thus, KL-6 might be a useful serological marker to distinguish CC patients from HCC patients.
背景/目的：KL-6粘蛋白是MUC1粘蛋白的一种。作者之前的免疫组织化学研究显示，在肝癌组织中，KL-6粘蛋白仅在肝内胆管癌（CC）中表达，而在肝细胞癌（HCC）中不表达。本研究进行了血清学分析，以评估各类肝癌患者和健康个体血清中的KL-6粘蛋白水平。
采用酶联免疫吸附测定法检测8例CC患者、27例HCC患者、30例转移性肝癌（MC）患者和19例健康个体血清中的KL-6粘蛋白水平。
CC患者血清KL-6粘蛋白水平显著高于健康个体（p<0.0001）、HCC患者（p<0.0001）和MC患者（p<0.001）。受试者工作特征分析确定血清KL-6粘蛋白水平的临界值为240 U/mL（CC与健康个体比较，p<0.001）或248 U/mL（CC与HCC比较，p<0.001）。以248 U/mL作为临界值，CC患者、健康个体和HCC患者的阳性率分别为100.0%、15.8%和18.5%。
在CC患者中可检测到血清KL-6水平升高。因此，KL-6可能是区分CC患者与HCC患者的有用血清学标志物。
